IL1B and deep vein thrombosis: The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial showed that patients with a history of AMI and an enhanced inflammatory response illustrated by hs-CRP levels of >2 mg/L, who were treated with 150 mg of canakinumab (monoclonal antibody targeting Il-1β), presented significantly lower MACE rates during a median follow-up of 3.7 years, as well as lower hs-CRP levels during follow-up, in comparison with the placebo group, and also with the lower dose canakinumab group (50 mg/day) [69].